• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 430642 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414713261 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414713261 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Shares of Acadia Pharmaceuticals Rise Above Previous 52-Week High

Published on Mon, 01/28/2013 - 15:11
By Peter Chu

Acadia Pharmaceuticals (NASDAQ:ACAD) traded at a new 52-week high today of $6.67. Approximately 6.4 million shares have changed hands today, as compared to an average 30-day volume of 2.1 million shares.

In the past 52 weeks, shares of Acadia Pharmaceuticals have traded between a low of $1.29 and a high of $6.67 and are now at $6.62, which is 413% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 7.0% while the 200-day MA has risen 3.4%.

Potential upside of 26.2% exists for Acadia Pharmaceuticals, based on a current level of $6.62 and analysts' average consensus price target of $8.36. The stock should discover initial support at its 50-day moving average (MA) of $4.48 and subsequent support at its 200-day MA of $2.48.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Take-Two Interactive Software Looks to C...

Shares of Take-Two Interactive Software (NASDAQ:TTWO) traded at a new 52-week high toda ...

Shares of Talisman Energy Fall Below Pre...

Shares of Talisman Energy (NYSE:TLM) traded at a new 52-week low today of $6.12. Appro ...

Recent 52-Week High Exceeded in Shares o...

Shares of Hanover Insurance (NYSE:THG) traded at a new 52-week high today of $66.88. T ...

Recent 52-Week Low Surpassed in Shares o...

Shares of Taseko Mines (AMEX:TGB) traded at a new 52-week low today of $1.35. This new ...

Transglobe Energy Looks to Continue to T...

Shares of Transglobe Energy (NASDAQ:TGA) traded today at $4.35, breaking its 52-week lo ...

Shares of TFS Financial Rise Above Previ...

Shares of TFS Financial (NASDAQ:TFSL) traded today at $15.09, breaking its 52-week high ...

Watch for Continued Gains in Shares of T...

Teva Pharmaceutical Industries (NASDAQ:TEVA) traded at a new 52-week high today of $55. ...

Shares of Integrys Energy Rise to a New ...

Integrys Energy (NYSE:TEG) traded at a new 52-week high today of $72.23. So far today ...